Tarafenacin D-tartrate is primarily used in the field of medicine as a selective antagonist for the muscarinic M3 receptor. Its main application is in the treatment of overactive bladder (OAB) syndrome, where it helps to reduce symptoms such as urinary urgency, frequency, and incontinence. By blocking the M3 receptors in the bladder, it decreases involuntary bladder contractions, allowing for better control over urination. This makes it a valuable therapeutic option for patients seeking relief from the discomfort and disruption caused by OAB. Additionally, its selectivity for the M3 receptor minimizes side effects compared to non-selective antimuscarinic agents, improving patient compliance and overall treatment outcomes.